New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 19, 2014
13:00 EDTNKTRNektar presents data from Phase l study of etirinotecan pegol
Nektar presented favorable data today from a Phase 1 study of etirinotecan pegol, EP, NKTR-102, in combination with 5-fluorouracil, 5-FU/Leucovorin LV, in patients with advanced cancer. NKTR-102 is the first long-acting topoisomerase I-inhibitor designed to concentrate in tumor tissue, provide sustained tumor suppression throughout the entire chemotherapy cycle, and to reduce the peak exposures that are associated with toxicities of other cytotoxics. These new data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for NKTR

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use